A cell-targeted chemotherapeutic nanomedicine strategy for oral squamous cell carcinoma therapy

Journal of Nanobiotechnology

Volumn 13, Issue 1, 2015, Pages

  Wang, Zhi Qi ^a   Liu, Kai ^a   Huo, Zhi Jun ^a   Li, Xiao Chen ^b   Wang, Min ^c   Liu, Ping ^d   Pang, Bo ^e   Wang, Shi Jiang ^a  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^c Second People's Hospital of Liaocheng   (China)

^d SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^e SHANDONG UNIVERSITY   (China)

Author keywords

Antitumor efficacy; Cisplatin (CDDP); Oral squamous cell carcinoma; Polymeric micelles

Indexed keywords

CELL DEATH; CHEMOTHERAPY; CYTOLOGY; CYTOTOXICITY; DISEASES; DRUG PRODUCTS; MEDICAL NANOTECHNOLOGY; MICELLES; NANOPARTICLES; PLATINUM COMPOUNDS;

ANTI-TUMOR EFFICACY; ANTICANCER EFFECTS; CISPLATIN; INTRACELLULAR UPTAKE; NANO-SIZED PARTICLES; ORAL SQUAMOUS CELL CARCINOMATA; POLYMERIC MICELLE; TARGETED NANOPARTICLE;

CELLS;

CISPLATIN; DRUG CARRIER; MACROGOL POLYGLACTIN NR7 PEPTIDE NANOPARTICLE; NANOPARTICLE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; LACTIC ACID; PEPTIDE; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

APOPTOSIS; ARTICLE; CELL KILLING; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG POTENCY; DRUG RELEASE; DRUG UPTAKE; FEASIBILITY STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNALIZATION; NANOMEDICINE; PARTICLE SIZE; PHYSICAL CHEMISTRY; SQUAMOUS CELL CARCINOMA CELL LINE; ANIMAL; CARCINOMA, SQUAMOUS CELL; CHEMISTRY; DRUG EFFECTS; MOUTH NEOPLASMS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CISPLATIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; LACTIC ACID; MOUTH NEOPLASMS; NANOMEDICINE; NANOPARTICLES; PEPTIDES; POLYGLYCOLIC ACID;

EID: 84942572638     PISSN: None     EISSN: 14773155     Source Type: Journal    
DOI: 10.1186/s12951-015-0116-2     Document Type: Article

References (22)

1. Lopes CF, de Angelis BB, Prudente HM, de Souza BV, Cardoso SV, de Azambuja Ribeiro RI. Concomitant consumption of marijuana, alcohol and tobacco in oral squamous cell carcinoma development and progression: recent advances and challenges. Arch Oral Biol. 2012;57:1026-33.
2. Kademani D, Bell RB, Brian. Oral and maxillofacial surgeons treating oral cancer: a preliminary report from the American Association of Oral and Maxillofacial Surgeons Task Force on Oral Cancer. J Oral Maxillofac Surg. 2008;66(2151):2157.
3. Woolgar JA, Triantafyllou A. A histopathological appraisal of surgical margins in oral and oropharyngeal cancer resection specimens. Oral Oncol. 2005;41:1034-43.
4. Rosenthal EL, Kulbersh BD, Duncan RD, et al. In vivo detection of head and neck cancer orthotopic xenografts by immunofluorescence. Laryngoscope. 2006;116(1636):1641.
5. Chen SF, Nieh S, Jao SW, et al. Quercetin suppresses drug-resistant spheres via the p38 MAPK-Hsp27 apoptotic pathway in oral cancer cells. PLoS One. 2012;7:49275.
6. Zhang P, Zhang Z, Zhou X, Qiu W, Chen F, Chen W. Identification of genes associated with cisplatin resistance in human oral squamous cell carcinoma cell line. BMC Cancer. 2006;6:224-34.
7. Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N Engl J Med. 1997;337(242):254.
8. Dhar S, Kolishetti N, Lippard SJ, Farokhzad OC. Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc Natl Acad Sci USA. 2011;108:1850-5.
9. Galanski M, Jakupec MA, Keppler BK. Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches. Curr Med Chem. 2005;12:2075-94.
10. Aranya I, Safirsteina RL. Cisplatin nephrotoxicity. Semin Nephrol. 2003;23(460):464.
11. Brillet G, Deray G, Jacquiaud C, Mignot L, Bunker D, Meillet D, Raymond F, Jacobs C. Long-term renal effect of cisplatin in man. Am J Nephrol. 1994;14(81):84.
12. Avgoustakis K. Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery. Curr Drug Deliv. 2004;1:321-33.
13. Betancourt T, Byrne JD, Sunaryo N, et al. PEGylation strategies for active targeting of PLA/PLGA nanoparticles. J Biomed Mater Res A. 2009;91(263):276.
14. Pal SK, Figlin RA, Reckamp K. Targeted therapies for non-small cell lung cancer: an evolving landscape. Mol Cancer Ther. 2010;9:1931-44.
15. Kolonin MG, Bover L, Sun J, et al. Ligand-directed surface profiling of human cancer cells with combinatorial peptide libraries. Cancer Res. 2006;66:34-40.
16. Harris RC, Chung E, Coffey RJ. EGF receptor ligands. Exp Cell Res. 2003;284(2):13.
17. Master AM, Qi Y, et al. EGFR-mediated intracellular delivery of Pc 4 nanoformulation for targeted photodynamic therapy of cancer: in vitro studies. Nanomed Nanotech Biol Med. 2012;8:655-64.
18. Ramasamy T, Tran TH, Choi JY, et al. Layer-by-layer coated lipid-polymer hybrid nanoparticles designed for use in anticancer drug delivery. Carbohydr Polym. 2014;102:653-61.
19. Savic R, Eisenberg A, Maysinger D. Block copolymer micelles as delivery vehicles of hydrophobic drugs: micelle-cell interactions. J Drug Target. 2006;14:343-55.
20. Allen C, Yu Y, Eisenberg A, Maysinger D. Cellular internalization of PCL(20)-b-PEO(44) block copolymer micelles. Biochim Biophys Acta. 1999;1421:32-8.
21. Xiong XB, Mahmud A, Uludag H, Lavasanifar A. Conjugation of arginine-glycine-aspartic acid peptides to poly(ethylene oxide)-bpoly(epsilon-caprolactone) micelles for enhance intracellular drug delivery to metastatic tumor cells. Biomacromolecules. 2007;8(874):884.
22. Zeng F, Lee H, Allen C. Epidermal growth factor-conjugated poly(ethylene glycol)-block-poly(delta-valerolactone) copolymer micelles for targeted delivery of chemotherapeutics. Bioconjug Chem. 2006;17(399):409.